DiNAMIQS
www.dinamiqs.comDiNAMIQS is a Contract Development and Manufacturing Organization (CDMO) revolutionizing gene therapy manufacturing and analytics. Based in Central Europe’s biotechnology hub Bio-Technopark Schlieren-Zürich, our state-of-the-art facility provides a comprehensive range of viral vector process development, manufacturing and analytical solutions to support and optimize the most promising gene therapy projects. With our innovative customized business interaction solutions, DiNAMIQS accelerates time to the clinic for its partners while reducing cost and risk. Our facility offers potent genetic medicine delivery vectors including high quality recombinant adeno-associated viral (AAV) vector manufacturing suitable for both in vitro and in vivo R&D applications up to 50L scale. Our highly skilled team has demonstrated success in biomanufacturing processes with more than 20 years’ experience in the field. DiNAMIQS is currently building a GMP-compliant facility that can produce viral vectors at 500L scale. Our team is led by Dr. Eduard Ayuso, one of the world’s leading experts in viral vector manufacturing and quality control. We serve clients globally from Bio-Technopark Schlieren-Zürich, the leading center for biotechnology companies in Central Europe, and home to our 1200 sqm state-of-the-art facility.
Read moreDiNAMIQS is a Contract Development and Manufacturing Organization (CDMO) revolutionizing gene therapy manufacturing and analytics. Based in Central Europe’s biotechnology hub Bio-Technopark Schlieren-Zürich, our state-of-the-art facility provides a comprehensive range of viral vector process development, manufacturing and analytical solutions to support and optimize the most promising gene therapy projects. With our innovative customized business interaction solutions, DiNAMIQS accelerates time to the clinic for its partners while reducing cost and risk. Our facility offers potent genetic medicine delivery vectors including high quality recombinant adeno-associated viral (AAV) vector manufacturing suitable for both in vitro and in vivo R&D applications up to 50L scale. Our highly skilled team has demonstrated success in biomanufacturing processes with more than 20 years’ experience in the field. DiNAMIQS is currently building a GMP-compliant facility that can produce viral vectors at 500L scale. Our team is led by Dr. Eduard Ayuso, one of the world’s leading experts in viral vector manufacturing and quality control. We serve clients globally from Bio-Technopark Schlieren-Zürich, the leading center for biotechnology companies in Central Europe, and home to our 1200 sqm state-of-the-art facility.
Read moreCountry
Industry
Employees
1-10
Founded
2022
Estimated Revenue
$1,000,000 to $5,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Head of Analytical Development
Email ****** @****.comPhone (***) ****-****Head of Business Development
Email ****** @****.comPhone (***) ****-****Head of Manufacturing - Preclinical Gene Therapy
Email ****** @****.comPhone (***) ****-****